[18F]AlF-NOTA-FAPI-04用于类风湿关节炎PET显像的临床前评价与初步临床研究
本研究开发了铝-[18F]标记的FAP抑制剂[18F]AlF-NOTA-FAPI-04,在类风湿关节炎(RA)成纤维样滑膜细胞、胶原诱导性关节炎(CIA)小鼠及2例RA患者中评估其显像性能。结果显示该探针在FAP高表达细胞和炎性关节中摄取增高,与关节炎评分正相关(Pearson r=0.834,P<0.001),并可被过量未标记FAPI-04阻断。作者认为该探针有望用于RA成纤维样滑膜细胞显像,可能补充现有无创诊断参数。
要点
- [18F]AlF-NOTA-FAPI-04在RA成纤维样滑膜细胞和FAP过表达NIH3T3细胞中结合显著高于对照。
- CIA小鼠炎性关节摄取与关节炎评分正相关(Pearson r=0.834,P<0.001),且可被过量未标记FAPI-04阻断。
- 2例RA患者PET/CT显示关节炎性关节滑膜非生理性高摄取。
核心结论
- [18F]AlF-NOTA-FAPI-04是用于RA成纤维样滑膜细胞显像的有前景放射性示踪剂,可能补充现有无创诊断参数。
研究设计与样本
- 体外结合研究使用RA成纤维样滑膜细胞和转染FAP的NIH3T3细胞,正常DBA1小鼠进行生物分布。
- 不同关节炎评分的CIA模型接受[18F]AlF-NOTA-FAPI-04和18F-FDG PET显像,并进行组织学检查评估FAP表达和Cy3-FAPI-04摄取。
- CIA小鼠和免疫缺陷小鼠NIH3T3移植瘤中用过量未标记FAPI-04进行阻断实验评估结合特异性。
- 对2例RA患者进行[18F]AlF-NOTA-FAPI-04 PET显像。
主要发现
- [18F]AlF-NOTA-FAPI-04在FAP-GFP-NIH3T3细胞结合为2.40 ± 0.078% AD/105 cells,高于GFP-NIH3T3细胞的0.297 ± 0.05% AD/105 cells。
- [18F]AlF-NOTA-FAPI-04在RA FLSs结合为1.54 ± 0.064% AD/105 cells,高于OA FLSs的0.343 ± 0.056% AD/105 cells。
- 与18F-FDG相比,[18F]AlF-NOTA-FAPI-04在关节炎早期炎性关节中显示高摄取,且与关节炎评分正相关(Pearson r=0.834,P<0.001)。
- [18F]AlF-NOTA-FAPI-04与高表达FAP细胞的结合及炎性关节摄取均可被过量未标记FAPI-04阻断。
- [18F]AlF-NOTA-FAPI-04在FAP-GFP-NIH3T3移植瘤摄取为35.44 ± 4.27% ID/mL,高于GFP-NIH3T3移植瘤的7.92 ± 1.83% ID/mL。
关键数值与推荐
- 体外结合以% AD/105 cells表示:FAP-GFP-NIH3T3 2.40 ± 0.078 vs GFP-NIH3T3 0.297 ± 0.05。
- 体外结合以% AD/105 cells表示:RA FLSs 1.54 ± 0.064 vs OA FLSs 0.343 ± 0.056。
- 移植瘤摄取以% ID/mL表示:FAP-GFP-NIH3T3 35.44 ± 4.27 vs GFP-NIH3T3 7.92 ± 1.83。
- 炎性关节摄取与关节炎评分正相关(Pearson r=0.834,P<0.001)。
临床怎么用
- [18F]AlF-NOTA-FAPI-04 PET/CT在RA患者中显示关节炎性关节滑膜非生理性高摄取。
- 作者认为[18F]AlF-NOTA-FAPI-04是用于RA FLSs显像的有前景示踪剂,可能补充现有无创诊断参数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibroblast-like synoviocytes (FLSs) are key effector cells in the inflamed joints of patients with rheumatoid arthritis (RA). Previous studies have suggested that fibroblast activation protein (FAP) is highly expressed in RA-derived FLSs and is a specific marker of activated RA FLSs. In this study, we developed aluminum-[18F]-labeled 1,4,7-triazacyclononane-N,N',N″-triacetic acid-conjugated FAP inhibitor 04 ([18F]AlF-NOTA-FAPI-04) to image RA-FLSs in vitro and arthritic joints in collagen-induced arthritis (CIA) mice and RA patients. METHODS: RA FLSs and NIH3T3 cells transfected with FAP were used to perform in vitro-binding studies. Biodistribution was conducted in normal DBA1 mice. Collagen-induced arthritis (CIA) models with different arthritis scores were subjected to [18F]AlF-NOTA-FAPI-04 and 18F-FDG PET imaging. Histological examinations were performed to evaluate FAP expression and Cy3 dye-labeled FAPI-04(Cy3-FAPI-04) uptake. Blocking studies with excess unlabeled FAPI-04 in CIA mice and NIH3T3 xenografts in immunocompromised mice were used to evaluate the binding specificity of [18F]AlF-NOTA-FAPI-04. Additionally, [18F]AlF-NOTA-FAPI-04 PET imaging was performed on two RA patients. RESULTS: The binding of [18F]AlF-NOTA-FAPI-04 increased significantly in RA FLSs and NIH3T3 cells overexpressing FAP compared to their parental controls (FAP-GFP-NIH3T3 vs. GFP-NIH3T3, 2.40 ± 0.078 vs. 0.297 ± 0.05% AD/105 cells; RA FLSs vs. OA FLSs, 1.54 ± 0.064 vs. 0.343 ± 0.056% AD/105 cells). Compared to 18F-FDG imaging, [18F]AlF-NOTA-FAPI-04 showed high uptake in inflamed joints in the early stage of arthritis, which was positively correlated with the arthritic scores (Pearson r=0.834, P<0.001). In addition, the binding of [18F]AlF-NOTA-FAPI-04 to cells with high FAP expression and the uptake of [18F]AlF-NOTA-FAPI-04 in arthritic joints both could be blocked by excessive unlabeled FAPI-04. Fluorescent staining showed that the intensity of Cy3-FAPI-04 binding to FAP increased accordingly as the expression of FAP protein increased in cells and tissue sections. Furthermore, the uptake of [18F]AlF-NOTA-FAPI-04 in FAP-GFP-NIH3T3 xenografts was significantly higher than that in GFP-NIH3T3 xenograft (35.44 ± 4.27 vs 7.92 ± 1.83% ID/mL). Finally, [18F]AlF-NOTA-FAPI-04 PET/CT imaging in RA patients revealed nonphysiologically high tracer uptake in the synovium of arthritic joints. CONCLUSION: [18F]AlF-NOTA-FAPI-04 is a promising radiotracer for imaging RA FLSs and could potentially complement the current noninvasive diagnostic parameters.
引用
- Ge L, Fu Z, Wei Y, et al. Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2022. PMID: 35715613. doi:10.1007/s00259-022-05836-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。